CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

BioSpace
Original article

From Big Pharma to specialty: why moving closer to the patient changes everything

Neutral
AI Analysis

Summary

SERB Pharmaceuticals executive Thomas Kolaras discusses the transition from Big Pharma to midsize specialty companies and the opportunities such a move presents for leadership and strategic thinking.

Importance:1/10
Sentiment:
0.00
corporateleadershipindustry_commentary

Read the original article

Published by BioSpace on July 22, 2026 7:01 AM

Read Original